• Register Today
  • Meeting Highlights in Multiple Myeloma From the 2015 European Hematology Association Annual Congress
  • ASCO 2015 Meeting Highlights
  • New Paradigms and Emerging Frontiers: The Immunotherapy Revolution in Multiple Myeloma
  • Risk Stratification Curriculum
  • Clinical Dialogues™ in Multiple Myeloma
  • Join Today
  • ASH 2014 Meeting Highlights
  • Earn CME Now

What's New

European Medicines Agency Accepts Ixazomib's Marketing Authorization Application for Patients with Relapsed/Refractory Multiple Myeloma
Missed out on this year’s EHA meeting in Vienna? We have you covered! – Slides from our live satellite symposium in Vienna, Austria - Shifting Paradigms in Multiple Myeloma: Future Insights to Practice

Revised International Staging System for Multiple Myeloma has Been Made Available: As Discussed in a Report From the International Myeloma Working Group (IMWG) published in the Journal of Clinical Oncology.

August 4, 2015 - Guidelines for the new Revised International Staging System (R-ISS) have been introduced by the IMWG to provide more accurate prognosis in newly diagnosed patients.

Developed in a large sample size of 3,060 patients, the R-ISS for multiple myeloma is a new risk-stratification algorithm with improved prognostic power compared to the three already widely used individual prognostic indicators it incorporates: (1) the ISS; (2) chromosomal abnormalities by iFISH; and (3) LDH sera level. In newly diagnosed multiple myeloma patients, the R-ISS allows for the identification of three distinct myeloma entities with significantly different survival outcomes.

Managing Myeloma will feature resources and activities that will assist you in navigating the new revised ISS, which all practitioners should incorporate into practice as the standard of care.

PubMed Abstract  Journal Link

Takeda Submits New Drug Application for Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma
Risk Stratification Curriculum
Diagnoses, Risk Assessment and Adaptive Therapeutic Strategies for Multiple Myeloma Management
This four-part, continuing education curriculum, presented as a Managing Myeloma exclusive, showcases new updates to diagnostic criteria and risk-stratification approaches for the diagnosis and treatment of multiple myeloma.
FAQ Library
Dr. Philip L. McCarthy answers new FAQs
Expert Perspectives
Expert Perspective in Multiple Myeloma: An Update on the New International Myeloma Working Group (IMWG) Guidelines
George Davatelis, PhD with Sagar Lonial, MD
Journal Club Library
Four recent abstracts with associated “Impact on Practice” are provided.
CE Activity
Annual Meeting HighlightsEHA Annual Meeting Highlights 2015 Live: Advances in Multiple Myeloma Treatment and Management
Sagar Lonial, MD; Paul G. Richardson, MD; Nikhil Munshi, MD; Antonio Palumbo, MD
CE Activity
Annual Meeting HighlightsASCO 2015: Highlights in Multiple Myeloma
Meletios A. Dimopoulos, MD; Sagar Lonial, MD; Donna E. Reece, MD; and Edward A. Stadtmauer, MD
CE Activity
Seeking Enhanced Management Strategies for Newly Diagnosed, Transplant-eligible Multiple Myeloma Patients
Paul G. Richardson, MD
CE Activity
Optimizing Outcomes in Multiple Myeloma: New Regimens and Sequencing Strategies for the Individual Patient
Robert Orlowski, MD, PhD
CE Activity
Clinical Discussion SeriesMultiple Myeloma Response Assessment and Tailoring Therapy
Edward A. Stadtmauer, MD
CE Activity
What Are the Current Trials Most Likely to Change Practice?
Noopur Raje, MD; Christopher Fausel, PharmD, MHA, BCOP; Tiffany Richards, MS, ANP, AOCNP
CE Activity
Evolving Treatment Goals and Addressing the Barrier of High-risk Disease Improved Outcomes
Shaji K. Kumar, MD; R. Donald Harvey III, PharmD, FCCP, BCOP; Beth Faiman, PhD, RN, MSN, APRN-BC, AOCN
CE Activity
What Are the Outstanding Questions Regarding Maintenance and Consolidation?
Noopur Raje, MD; Christopher Fausel, PharmD, MHA, BCOP; Tiffany Richards, MS, ANP, AOCNP